Under Armour Inc Class A (UAA) Stock Price Today
Key Stats
- $2.15BMarket Cap
- -Volume
- Consumer CyclicalSector
- $8.1452W High
- $4.1752W Low
- -Typical Hold Time
- $3.13BEnterprise Value
- -Div Yield
- -Trading Activity
Track Under Armour Inc Class A (UAA) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Under Armour Inc Class A has traded between a low of $4.17 and a high of $8.14, highlighting its annual price range. Buy and sell Under Armour Inc Class A shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Most Recent News
Automattic CEO Matt Mullenweg placed on leave; CFO Mark Davies named interim CEO amid board dispute.
Matt Mullenweg, founder and CEO of Automattic, was placed on a paid leave of absence by the company's board, with CFO Mark Davies appointed as interim CEO. Mullenweg opposed the decision, which was made without giving him time for legal review. The b...
US Treasury tripled bond buybacks but yields rose; Ron Paul warns against trusting Fort Knox gold accounting.
The US Treasury increased its bond buyback ceiling to $6 billion to ease borrowing costs, but 10-year yields still rose to 4.85%. Ron Paul criticized the government's gold accounting at Fort Knox, highlighting the outdated valuation of $42.22 per oun...
Axsome reports strong growth for its CNS drugs AUVELITY, SYMBRAVO, and SUNOSI with new Alzheimer's agitation launch underway.
Axsome Therapeutics, a biopharma company focused on central nervous system (CNS) disorders, reported robust growth for its three commercial products: AUVELITY (for major depressive disorder and Alzheimer's agitation), SYMBRAVO (for migraine), and SUN...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.